Realm Therapeutics (RLM) Share Price, News & Analysis

Company Overview

Realm Therapeutics Plc, a biopharmaceutical company, focuses on developing therapies for the treatment of immune-mediated diseases in adults and children. Its product pipeline includes PRO22, a topical gel, which is conducting initial Phase II clinical studies for the treatment of atopic dermatitis. The company was formerly known as PuriCore plc and changed its name to Realm Therapeutics Plc in December 2016. Realm Therapeutics Plc was founded in 2016 and is headquartered in Malvern, Pennsylvania.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 169,853 shs
• Average Volume: 800,861 shs
• Market Capitalization: £13.41 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Steel Works
• Current Symbol: LON:RLM
• Previous Symbol: LON:PURI
• CIK: N/A
• Web: www.realmtx.com
• Phone: +1-484-3212700
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.05
• Quick Ratio: 9.96

Sales & Book Value

• Annual Sales: £501.92 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 0.57
• Book Value: GBX 20.80 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 116,562,000
• Free Float: N/A
• Market Cap: £13.41 million
• Optionable: Not Optionable
• Beta: N/A